Boehringer Ingelheim’s Pagnotta Talks Adalimumab And Interchangeability
As Cyltezo Rival To Humira Hits US, Firm Says It Is ‘Uniquely Positioned’ In Biosimilars Market
• By David Wallace
Stephen Pagnotta is biosimilar commercial brand lead at Boehringer Ingelheim • Source: Boehringer Ingelheim 
